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Testosterone Reduction Prevents Phenotypic
Expression in a Transgenic Mouse Model
of Spinal and Bulbar Muscular Atrophy
spinocerebellar ataxia, and dentatorubral and pallidolu-
ysian atrophy (DRPLA) (Zoghbi and Orr, 2000; Paulson,
2000). These polyQ diseases share several clinical find-
ings such as anticipation, somatic mosaicism (Tanaka
et al., 1999), and selective neuronal and non-neuronal
Masahisa Katsuno,1,4 Hiroaki Adachi,1,4
Akito Kume,1 Mei Li,1 Yuji Nakagomi,2
Hisayoshi Niwa,1 Chen Sang,1 Yasushi Kobayashi,1
Manabu Doyu,1 and Gen Sobue1,3
1Department of Neurology
Nagoya University Graduate School of Medicine involvement despite widespread expression of the mu-
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Showa-ku, Nagoya 466-8550 is also an inverse correlation between the CAG repeat
size and the age at onset, or the disease severity ad-Japan
2 Laboratory of Electron Microscopy justed by the age at examination in SBMA (Doyu et al.,
1992; La Spada et al., 1992; Igarashi et al., 1992) as wellAichi Medical University
21 Karimata, Yazako as other polyQ diseases (Duyao et al., 1993; Orr et al.,
1993; Zoghbi and Orr, 2000; Paulson, 2000).Nagakute-cho, Aichi 480-1195
Japan Previously, we reported nuclear inclusions (NIs) con-
taining the mutant and truncated AR with expanded
polyQ in the residual motor neurons in the brain stem
and spinal cord (Li et al., 1998a) as well as in the skin,Summary
testis, and some other visceral organs of SBMA patients
(Li et al., 1998b). The presence of NIs is a pathologicSpinal and bulbar muscular atrophy (SBMA) is a poly-
glutamine disease caused by the expansion of a CAG hallmark of most other polyQ diseases, and is consid-
ered to be relevant to pathophysiology (Zoghbi and Orr,repeat in the androgen receptor (AR) gene. We gener-
ated a transgenic mouse model carrying a full-length 2000; Paulson, 2000). However, considerable contro-
versy surrounds the importance of NIs in the pathophysi-AR containing 97 CAGs. Three of the five lines showed
progressive muscular atrophy and weakness as well ology of the polyQ diseases (Klement et al., 1998; Sau-
dou et al., 1998; Cummings et al., 1999; Gutekunst etas diffuse nuclear staining and nuclear inclusions con-
sisting of the mutant AR. These phenotypes were al., 1999). NIs may reflect a cellular mechanism that
protects neurons from the toxic effects of polyQ tract,markedly pronounced in male transgenic mice, and
dramatically rescued by castration. Female transgenic and nuclear translocation of the mutant protein may be
essential in the pathophysiology of the majority of polyQmice showed only a few manifestations that markedly
deteriorated with testosterone administration. Nu- diseases. SBMA is unique among these disorders in that
the mutant protein, AR, has a specific ligand, testoster-clear translocation of the mutant AR by testosterone
contributed to the phenotypic difference with gender one, and this ligand alters the subcellular localization of
the protein by favoring its nuclear uptake. The AR isand the effects of hormonal interventions. These re-
sults suggest the therapeutic potential of hormonal normally confined to a multi-heteromeric inactive com-
plex in the cell cytoplasm, and translocates into theintervention for SBMA.
nucleus in a ligand-dependent manner (Zhou et al.,
1994), which is likely enhanced in male SBMA patients.Introduction
We took advantage of this ligand effect to study the role
of nuclear uptake of the mutant protein on the diseaseSpinal and bulbar muscular atrophy (SBMA) is an X-linked
late-onset motor neuron disease characterized by proxi- manifestations in transgenic (Tg) mice.
Unlike the profound gender difference of phenotypesmal muscle atrophy, weakness, contraction fascicula-
tions, and bulbar involvement (Kennedy et al., 1968; in SBMA patients, neither a Tg mouse model of SBMA
expressing expanded pure 239 CAGs under the controlSobue et al., 1989). Heterozygous female carriers are
usually asymptomatic, although some express subclini- of human AR promoter (Adachi et al., 2001) nor that
carrying truncated AR with 112 CAGs (Abel et al., 2001)cal phenotypes, including high amplitude motor unit po-
tentials on electromyography (Sobue et al., 1993; Mari- showed any remarkable phenotypic difference with gen-
der. In the present study, we generated Tg mice withotti et al., 2000). A specific treatment for SBMA has
not been established. Testosterone may improve motor full-length AR containing 97 CAGs, showing neurologic
phenotypes with significant sexual differences. Our find-function in some patients, although it has no effects on
the progression of SBMA (Danek et al., 1994; Goldenberg ings reiterate the importance of nuclear localization of
the mutant protein in the disease mechanism, and indi-and Bradley, 1996; Neuschmid-Kaspar et al., 1996).
The molecular basis of SBMA is the expansion of a cate an approach to effective treatment for SBMA.
trinucleotide CAG repeat in the first exon of the andro-
gen receptor (AR) gene, which encodes the polygluta- Results
mine (polyQ) tract (La Spada et al., 1991). Thus, SBMA
was the first described member of polyQ diseases in- Tg Mice Carrying Full-Length Human AR with 97
cluding Huntington’s disease (HD), several forms of CAGs Showed Sexual Differences in Symptoms,
Transgene Expression, and Pathology
Symptomatic difference with gender: we generated Tg3Correspondence: sobueg@med.nagoya-u.ac.jp
4 These authors contributed equally to this work. mice expressing the full-length human AR containing
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Figure 1. Sexual Differences in Symptomatic
Phenotypes and Transgene Expression
(A) Schematic view of the transgene con-
structs. The microinjected fragment was
composed of a cytomegalovirus enhancer
(E), a chicken -actin promoter (Pro), a full-
length human AR containing 24 or 97 CAGs
(hAR), and a rabbit -globin polyadenylation
signal sequence (polyA). (B, C, D, and E) Sex-
ual differences in body weight (B, #2–6), ro-
tarod task (C, #7–8), cage activity (D, #2–6),
and survival rate (E, #7–8). All parameters are
significantly different between the male AR-
97Q mice (, n 8) and female AR-97Q mice
(, n  8) (p  0.001, p  0.003, p  0.005,
and p  0.001, respectively). (F) Western blot
analysis of total homogenates from the mus-
cle of the male (M) and female (F) mice of
AR-97Q, AR-24Q, and normal littermates (12-
week-old) immunolabeled by an antibody
(N-20) against AR. Mouse AR was hardly de-
tectable in the normal littermates. Compari-
son with muscle extracts from normal lit-
termates indicated that most of the lower
bands in transgenic (Tg) mice represent trun-
cated human AR. Protein lysate from Neuro2a
cells transfected with the transgene con-
taining 24 CAGs and that with 97 CAGs (AR24
and AR97) are shown for size comparison.
(G) Western blot analysis of nuclear (N) and
cytoplasmic (CY) fractions from the muscle
of the male (M) and female (F) AR-97Q mice
(#7–8, 14-week-old) immunolabeled by N-20.
24 or 97 CAGs under the control of a cytomegalovirus 97Q mice regardless of the line (Figures 1B–1E). The
first detectable phenotype is muscle atrophy of the trunkenhancer and a chicken -actin promoter (Figure 1A).
We established 3 lines with 24 glutamines (AR-24Q) and and hindlimbs followed by weight loss and impairment
of the rotarod task. We detected the onset of motor5 lines with 97 glutamines (AR-97Q). Copy numbers of
the transgene were 1 to 5 in AR-24Q mice and 1 to 3 in impairment by the rotarod task at 8 to 9 weeks of age
in the male AR-97Q mice, while 15 weeks or more in theAR-97Q mice (Table 1). We assessed the 24 or 97 CAG
repeat in the transgene by the PCR amplification on females (Table 1). The affected mice were hypoactive
and dragged their hindlimbs. The forelimbs were notthe tail DNA using a fluorescently labeled primer, and
subsequent size determination on the polyacrylamide involved until hindlimb atrophy became severe. Males
showed a markedly faster and earlier motor deficit thangel did not show unequivocal intergenerational instabil-
ity in the CAG repeat number (data not shown). females, and shorter life span. The 50% mortality ranged
from 66 to 132 days of age in the male AR-97Q mice ofThree of five lines with AR-97Q (#2–6, #4–6, #7–8)
exhibited progressive motor impairment, although no 3 lines, whereas mortality of the female AR-97Q mice
remained only 10% to 30% at more than 210 days inlines with AR-24Q showed any manifested phenotypes
up to the latest age examined, 30 weeks old. All three the 3 lines. The cause of death was cachexia due to
hyponutrition and dehydration.symptomatic lines showed small body size, short life
span, progressive muscle atrophy and weakness, as Expression of transgene: Western blot analysis re-
vealed the transgenic protein retained in the stackingwell as reduced cage activity, all of which were markedly
pronounced and accelerated in the male AR-97Q mice, gel as well as a single band of AR monomer consistent
with 97 glutamines and truncated fragments of mutantbut not observed or far less severe in the female AR-
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Table 1. Phenotypes of Transgenic Mice
Onset of Weight Loss Onset of Rotarod Impairment Median Life Expectancy
Line Copy Number (Weeks) (Weeks) (Days) 1C2 Staining
AR-97Q
2–6 1–3 6/16 9/18 66/210 /
4–6 1–3 4/12 8/15 110/210 /
7–8 1–3 8/16 9/21 132/210 /
3–7 ND 8/ / 210 ND
8–5 ND 8/ / 210 ND
AR-24Q
5–5 5 / / ND /
8–7 1–3 / / ND
12–13 1–3 / / ND ND
Data is shown as male/female. , not detected; , detectable diffuse nuclear staining and nuclear inclusions; , abundant diffuse nuclear
staining and nuclear inclusions; ND, not determined. All mice were examined until 30 weeks old.
AR in all symptomatic lines. We detected these proteins Pathology: AR-24Q mice showed no pathologic ab-
normalities at the age of 12 weeks. In AR-97Q mice, wein the spinal cord, cerebrum, heart, muscle, and pan-
creas. Although the male AR-97Q mice had more protein detected diffuse nuclear staining and less frequent NIs
with 1C2, an antibody specifically recognizing the ex-within the stacking gel than the female AR-97Q mice, the
female AR-97Q mice had more monomeric AR protein panded polyQ (Trottier et al., 1995), in the neurons of
the spinal cord, cerebrum, cerebellum, brain stem, and(Figure 1F). AR-24Q mice showed a single band of AR
with 24 glutamines without protein in the stacking gel. dorsal root ganglia as well as non-neuronal tissue such
as the heart, muscle, and pancreas (Table 2). In theThe nuclear fraction contained the most transgene pro-
tein within the stacking gel (Figure 1G). neuronal tissues, the nuclei of the motor neurons
showed the most prominent diffuse nuclear staining andThere was no significant difference in the expression
of the mRNA of the transgene between the male and NIs. Glial cells also showed marked staining, but not the
dorsal root ganglia. The regions with diffuse nuclearfemale AR-97Q mice (data not shown). These observa-
tions indicate that the nuclear localization is the major staining and NIs also showed immunoreactivity to an
antibody to AR (N-20) (data not shown). Neither 1C2expression profile of the transgene protein in the stack-
ing gel. This nuclear localization was more prominent nor N-20 revealed immunoreactivity in the cytoplasm.
Diffuse nuclear staining and NIs were found at 4 weeksin males than in females, while the mRNA expression
levels were indistinguishable between genders. of age and became more profound with aging, although
Table 2. Distribution of Nuclear Inclusions and Diffuse Nuclear Staining with 1C2
Male Female
Tissue Nuclear Inclusions (NIs)/Diffuse Nuclear Staining (D) Nuclear Inclusions (NIs)/Diffuse Nuclear Staining (D)
Neuronal Total NIs/D Neuronal NIs/D Glial NIs/D Total NIs/D Neuronal NIs/D Glial NIs/D
Cerebral cortex / / / / / /
Olfactory bulb / / / / / /
Basal ganglia / / / / / /
Cerebellum / / / / / /
Pons / / / / / /
Ependyma / /
Spinal cord / / / / / /
Dosal root ganglia / / / / / /
Non-neuronal
Muscle / /
Heart / /
Pancreas / /
Eye / /
Lung / /
Kidney / /
Liver / /
Stomach / /
Intestine / /
Spleen / /
Thymus / /
Skin / /
Prostate 
Testis 
Ovary 
, absent;  mild; , moderate; , abundant. In the case that the amount of NIs or D differs among three lines, we delineate its range.
Three lines, #2–6, #4–6, and #7–8, were autopsied at 12, 18, 15 weeks of age, respectively.
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Figure 2. Pathologic Findings of AR-97Q Mice
(A) Immunohistochemical study of the spinal anterior horn and muscle of the male and female AR-97Q mice stained with a monoclonal antibody
(1C2) against abnormally expanded polyglutamine (#7–8, 14-week-old). (B–E) Electron microscopic immunohistochemistry for 1C2 of an anterior
horn cell (#4–6, 24-week-old). Dense granular aggregate of 1C2-immunoreactive material was recognized in the motor neuron nucleus which
showed a nuclear inclusion in light micrograph (B, low magnification and C, high magnification). Another motor neuron (D, arrow), which
demonstrated diffuse nuclear staining in light micrograph, showed microaggregates in high magnification (E). (F) HE staining of the muscle
in the male AR-97Q mouse revealed obvious grouped atrophy and small angulated fibers (arrow) (#7–8, 14-week-old). (G) Toluidine blue
staining and the histogram of myelinated fiber diameter of the L5 ventral root of male AR-97Q mice and their normal littermates. Large
myelinated fibers in the ventral root showed axonal atrophy in the male AR-97Q mice (, n  3) compared with normal littermates (, n  3)
(#7–8, 13-week-old).
male AR-97Q mice showed significantly more diffuse 10.29  1.08 m in their male littermates (p  0.05),
whereas that of small fibers (6.0 m) was 3.11  0.23nuclear staining and NIs than females in agreement with
the symptomatic and Western blot profile differences m in male AR-97Q and 2.86  0.11 m in their male
littermates (p  0.16). Female AR-97Q mice showed nowith gender (Table 2, Figure 2A). Electron microscopic
immunohistochemistry for 1C2 demonstrated granular neuropathic changes. Neuronal cell population in the
cerebrum, cerebellum, and dorsal root ganglia was fairlyaggregates corresponding to NIs and fine microaggre-
gates corresponding to diffuse nuclear staining in the well preserved despite the abundant diffuse nuclear
staining and NIs (data not shown).neuronal tissues (Figures 2B–2E).
Muscle histology revealed significant grouped atro-
phy and small angulated fibers in the male AR-97Q mice Castration Prevents Phenotypic Expression
in Male AR-97Q Miceas well as mild myopathic change such as increased
variability in muscle fiber size (Figure 2F). Although the Castrated male AR-97Q mice showed marked improve-
ment of symptoms, pathologic findings, and nuclearnumber of spinal motor neurons tended to be reduced
in AR-97Q mice, the difference was not significant; 452 localization of the mutant AR compared with the sham-
operated male AR-97Q mice. These castrated male AR-10/10 sections in L5 segment of AR-97Q mice and 543
28/10 sections in their littermates (p  0.10). Neverthe- 97Q mice weighed the same as their castrated male
littermates, whereas the sham-operated male AR-97Qless, the cross-sectional area of the individual spinal
motor neurons significantly decreased in the male AR- mice showed progressive emaciation (Figure 3A). Motor
impairment assessed by rotarod and cage activity was97Q mice: 130.6  4.0 m2 in L5 of male AR-97Q and
195.6  12.1 m2 in their male littermates (p  0.006). significantly less or virtually absent in the castrated male
AR-97Q mice as compared with the sham-operatedIn addition, the diameter of large myelinated fibers (	6.0
m) was significantly diminished in the male AR-97Q male AR-97Q mice (Figures 3B and 3C). The castrated
male AR-97Q mice showed motor impairment similar tomice (Figure 2G); the diameter of large fibers of the L5
ventral root was 8.49  0.27 m in male AR-97Q and that of the female AR-97Q mice. The life span was also
Testosterone Reduction Rescues SBMA Mouse 1
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Figure 3. Effects of Castration on the Symp-
tomatic Phenotypes of Male AR-97Q Mice
(A–D) Body weight (A, #7–8), rotarod task (B,
#7–8), cage activity (C, #7–8), and survival rate
(D, #2–6) of the castrated (, n 6) and sham-
operated (, n  6) male AR-97Q mice. All
parameters are significantly different be-
tween the sham-operated male AR-97Q mice
and the castrated male AR-97Q mice or cas-
trated male littermates (, n 2) (p 0.0001,
p  0.0001, p  0.006, and p  0.0006, re-
spectively). (E) The castrated AR-97Q mouse
(top) shows no muscular atrophy, which is
striking in the sham-operated male AR-97Q
mouse (bottom) (#2–6, 12-week-old). (F) Foot-
prints of 12-week-old castrated (C) and
sham-operated (S) male AR-97Q mice (#2–6).
Front paws are in red, and hind paws in blue
paint.
significantly prolonged in the castrated male AR-97Q in sham-operated male AR-97Q mice was 27.7  1.2
ng/dl (#7–8, n  4).mice (Figure 3D). The castrated AR-97Q mice showed
amelioration of muscle atrophy and body size reduction
(Figure 3E). In a footprint analysis, the sham-operated Testosterone Administration Deteriorates
Phenotypic Expression in Female Tg Micemale AR-97Q mice exhibited motor weakness with drag-
ging of their hindlegs, which improved in the castrated By contrast, testosterone administration markedly exac-
erbated symptoms, pathologic features, and nuclear lo-male AR-97Q mice (Figure 3F). In the Western blot analy-
sis using N-20, the mutant AR appearing within the calization of the mutant AR in the female AR-97Q mice.
The testosterone-administered female AR-97Q micestacking gel was markedly diminished in the castrated
male AR-97Q mice compared with the sham-operated showed progressive emaciation (Figure 5A). The motor
impairment assessed by rotarod and cage activity wasmale AR-97Q mice (Figure 4A). The mutant AR in the
nuclear fraction also significantly decreased in the cas- significantly worsened in the female AR-97Q mice ad-
ministered testosterone, being similar to those of thetrated male AR-97Q mice (Figure 4B). The castrated
male AR-97Q mice showed markedly diminished diffuse untreated male AR-97Q mice (Figures 5B and 5C). The
life span of the female AR-97Q mice was also affectednuclear staining and NIs (Figure 4C). These observations
suggested that castration markedly prevented nuclear by testosterone administration (Figure 5D). The testos-
terone-administered AR-97Q mice showed markedlocalization of the mutant AR protein. The serum testos-
terone in the castrated male AR-97Q mice dramatically muscle atrophy and body size reduction (Figure 5E).
In a footprint analysis, the testosterone-administereddecreased to an undetectable low level, whereas that
Neuron
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Figure 4. Effects of Castration on Transgene
Expression and Neuropathology of Male AR-
97Q Mice
(A) Western blot analysis of total homoge-
nates from the spinal cord and muscle of the
castrated (C) and sham-operated (S) male
AR-97Q mice, which were immunolabeled by
N-20 (#7–8, 13-week-old). (B) Western blot
analysis of nuclear (N) and cytoplasmic (CY)
fraction from the muscle of the castrated (C)
and sham-operated (S) male AR-97Q mice,
immunolabeled by N-20 (#7–8, 13-week-old).
(C) Immunohistochemical study using 1C2
showed marked differences of diffuse nuclear
staining and nuclear inclusions between the
castrated and sham-operated AR-97Q mice
in the spinal anterior horn and the muscle
(#7–8, 13-week-old).
female AR-97Q mice exhibited motor weakness and Discussion
dragged their hindlegs, which was not detected in the
sesame oil-administered female AR-97Q mice (Figure Our Tg mice with the full-length human AR containing
97 CAGs demonstrated progressive motor impairment5F). Western blot analysis using N-20 revealed the mu-
tant AR in the stacking gel in whole tissue homogenates and neuropathologic changes equivalent to human
SBMA. Western blot analysis showed truncated frag-as well as in the nuclear fraction, which was larger in
amount in the testosterone-administered female AR- ments of mutant AR in the affected tissues. These frag-
ments may contribute to pathophysiology in our Tg mice97Q mice than in the sesame oil-administered female
AR-97Q mice (Figures 6A and 6B). The testosterone- since several studies have suggested that proteolytic
cleavage of mutant protein plays an important role inadministered female AR-97Q mice demonstrated mark-
edly pronounced diffuse nuclear staining and NIs with the pathogenic mechanisms of SBMA as well as other
polyQ diseases (Li et al., 1998b; Kobayashi et al., 1998;1C2 compared with the sesame oil-administered female
AR-97Q mice (Figure 6C). The testosterone-adminis- Wellington et al., 1998; Mende-Mueller et al., 2001). Elec-
tron microscopic immunohistochemistry for 1C2 dem-tered female 97Q mice showed markedly higher serum
testosterone levels (158.0  70.7 ng/dl in #2–6, n  3; onstrated granular aggregates and fine microaggre-
gates, which indicates variable stages of pathologic305.3  182.3 ng/dl in #7–8, n  4) than those in the
sesame oil-administered female AR-97Q mice, all of change in the nucleus of motor neurons. Granular aggre-
gate has also been reported in the pathologic study ofwhich showed an undetectable low level.
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Figure 5. Effects of Testosterone Adminis-
tration on the Symptomatic Phenotypes of
Female AR-97Q Mice
(A–D) Body weight (A, #7–8), rotarod task (B,
#7–8), cage activity (C, #2–6), and survival rate
(D, #7–8) of the testosterone-administered (,
n  7) and sesame oil-administered (, n 
7) female AR-97Q mice. All parameters are
significantly different between the testoster-
one-administered female AR-97Q mice and
the sesame oil-administered female AR-97Q
mice or testosterone-administered female lit-
termates (, n  4) (p  0.0001). (E) The tes-
tosterone-administered AR-97Q mouse (top)
shows striking muscular atrophy, which is not
demonstrated in the sesame oil-administered
female AR-97Q mice (bottom) (#2–6, 14-
week-old). (F) Footprints of 14-week-old tes-
tosterone-administered (T) and sesame oil-
administered (O) female AR-97Q mice (#2–6).
SBMA (Li et al., 1998b). In our AR-97Q mice, neurogenic normalities in AR-24Q mice at 12 weeks of age. These
findings clarify that the symptomatic and pathologicchanges were evident in muscle pathology, and anterior
horn cells and their axons showed significant decrease phenotypes in AR-97Q were not due to overexpression
of human AR but due to expanded polyglutamine tract.in size without substantial neuronal loss. These findings
indicate that the main pathologic feature of our AR-97Q Moreover, no phenotypes were found in previous SBMA
Tg mice with full-length human AR despite good trans-mice was neuronal dysfunction rather than degeneration
of the spinal motor neurons, which was also demon- gene expression levels, presumably because the CAG
repeat was not long enough (Bingham et al., 1995; Lastrated in a number of Tg mouse models of other polyQ
diseases (Zoghbi and Orr, 2000; Rubinsztein, 2002). All Spada et al., 1998).
Several Tg mouse models of SBMA have been re-symptomatic mice with AR-97Q showed motor impair-
ment by 21 weeks of age; until this age, no lines with ported so far. Since early models failed to manifest neu-
rologic phenotypes (Bingham et al., 1995; La Spada etAR-24Q demonstrated rotarod deficit or weight loss in
spite of the same expression levels of AR protein and al., 1998; Merry et al., 1996), truncated AR and powerful
promoter have been used in order to enhance pheno-similar copy numbers of the transgene. Nuclear inclu-
sions and diffuse nuclear staining with 1C2 were found types. A Tg mouse model of SBMA expressing ex-
panded pure 239 CAGs under the control of human ARsince 4 weeks of age even in female AR-97Q mice, al-
though they are far less frequent than in male AR-97Q promoter (Adachi et al., 2001) and that carrying trun-
cated AR with 112 CAGs controlled by prion proteinmice. Nevertheless, pathologic studies showed no ab-
Neuron
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Figure 6. Effects of Testosterone Administra-
tion on Transgene Expression and Neuropa-
thology of Female AR-97Q Mice
(A) Western blot analysis of total homoge-
nates from the spinal cord and muscle of the
testosterone-administered (T) and sesame
oil-administered (O) female AR-97Q mice
which were immunolabeled by N-20 (#2–6,
12-week-old). (B) Western blot analysis of nu-
clear (N) and cytoplasmic (CY) fraction from
the muscle of the testosterone-administered
(T) and sesame oil-administered (O) female
AR-97Q mice, immunolabeled by N-20 (#2–6,
12-week-old). (C) Immunohistochemical study
using 1C2 showed marked differences of dif-
fuse nuclear staining and nuclear inclusions
between the testosterone-administered and
sesame oil-administered female AR-97Q mice
in the spinal anterior horn and the muscle
(#2–6, 12-week-old).
promoter (Abel et al., 2001) demonstrated progressive in our Tg mice, in which the transgene was not controlled
by its own promoter with androgen-responsive elementmotor deficits and neuronal inclusions. They showed,
however, no sexual difference of phenotypes because but by chicken -actin promoter. These observations
indicate that the testosterone level plays important rolesthe transgenes of these Tg mice did not contain the
ligand binding domain located in the C terminus of AR. in the sexual difference of phenotypes and effects of
hormonal interventions, especially in the posttranscrip-Another Tg mouse model with the full-length AR showed
motor impairment, although sexual difference of pheno- tional stage of the mutant AR.
Castration dramatically prevented the phenotypic ex-types has not been reported (Morrison et al., 2000).
The symptoms, pathologic findings, and nuclear local- pression including neurologic findings in the male AR-
97Q mice. The female AR-97Q mice, which showed few ifization of the mutant AR protein showed a remarkable
sexual difference in our AR-97Q mice, and were signifi- any manifestations, demonstrated marked deterioration
of symptoms by testosterone administration. The mu-cantly modified by hormonal intervention either by cas-
tration or testosterone administration. Although andro- tant AR located in the nuclei assessed by Western blot
analysis and by immunohistochemistry with 1C2 dra-gen has been shown to upregulate the expression of
AR (Syms et al., 1985; Kemppainen et al., 1992; Zhou matically diminished in the castrated male AR-97Q mice,
and markedly increased in the testosterone-adminis-et al., 1995), RT-PCR did not reveal any significant sexual
difference in the mRNA levels of the transgenic AR gene tered female AR-97Q mice. The castrated male AR-97Q
Testosterone Reduction Rescues SBMA Mouse 1
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mice showed undetectable serum testosterone levels, approaches to the polyQ diseases. In a Tg mouse model
whereas the testosterone-administered female AR-97Q of HD, expression of a dominant-negative caspase-1
mice showed markedly increased levels. Since the nu- mutant extended survival and delayed the appearance
clear translocation of AR is solely dependent on testos- of neuronal inclusions, neurotransmitter receptor alter-
terone (Stenoien et al., 1999; Simeoni et al., 2000), tes- ations, and onset of symptoms (Ona et al., 1999). Inhibi-
tosterone may show toxic effects in the female AR-97Q tion of mutant gene expression demonstrated the re-
mice by accelerating nuclear translocation of the mutant versibility of phenotypic progression in a Tg mouse
AR. By contrast, castration prevented the nuclear local- model of HD (Yamamoto et al., 2000). However, these
ization of the mutant AR by reducing the testosterone gene modulations cannot be directly applied clinically.
level. The nuclear localization of the mutant protein with Transglutaminase inhibitors suppressed aggregate for-
expanded polyQ is important in inducing neuronal cell mation and apoptosis in a cell model of DRPLA (Igarashi
dysfunction and degeneration in the majority of polyQ et al., 1998) and prolonged survival in a Tg mouse model
diseases. Addition of a nuclear export signal to the mu- of HD (Karpuj et al., 2002). An in vitro model of HD
tant huntingtin eliminates aggregate formation and cell showed inhibition of huntingtin fibrillogenesis by spe-
death in cell models of HD (Saudou et al., 1998; Peters cific antibodies and small molecules (Heiser et al., 2000).
et al., 1999), and a nuclear localization signal had the Creatine increased survival and delayed motor symp-
opposite effect (Peters et al., 1999). In Tg mice of SCA1 toms in a Tg mouse model of HD (Andreassen et al.,
having a mutated nuclear localization signal, ataxin-1 2001). Overexpression of molecular chaperone HSP70
was distributed in the cytoplasm, and the mice did not demonstrated preventive effects in a Drosophila model
show any neurologic disorders (Klement et al., 1998). of Machado-Joseph disease (Warrick et al., 1999) and
These findings suggest that reduction of testosterone SCA1 cell and Tg mouse models (Cummings et al., 1998,
ameliorates phenotypic expression by preventing nu- 2001). HSP70 and HSP40 showed preventive effects
clear localization of the mutant AR. We emphasize that also in an SBMA cell model (Kobayashi et al., 2000).
our approach, hormonal intervention to diminish testos- These and other therapeutic approaches have, yet, re-
terone level, can be applied to human therapy. mained insufficient or minimal in prevention of pheno-
The castrated AR-97Q mice showed phenotypes simi- typic expression and progression. Recently reported
lar to those of the female AR-97Q mice, implying that histone deacetylase inhibitors in a Drosophila model
motor impairment of SBMA patients can be rescued to could be a promising candidate therapy for polyQ dis-
the level in female carriers. Almost half of the human eases (Steffan et al., 2001), but their therapeutic efficacy
SBMA female carriers showed mild subclinical electro- should be assessed in a Tg mouse model. Although no
myographic abnormalities, while few manifested clinical specific ligand of the mutant protein has been revealed
phenotypes (Sobue et al., 1993; Mariotti et al., 2000). in other polyQ diseases, the striking therapeutic effects
Indeed, lower expression level of mutant AR in female of castration in our Tg mice further suggests that pa-
carriers due to X inactivation may cause the escape tients with polyQ disease can be rescued by prevention
from the manifestation, but our present study also sug- of the nuclear translocation of the mutant proteins. We
gests that the low level of testosterone prevents the emphasize that it is necessary to investigate hormone-
nuclear localization of the expressed mutant AR, re- like small molecules which alter the nuclear localization
sulting in a lack of phenotypic manifestations in the of mutant proteins for therapy of polyQ diseases.
female carriers.
A toxic gain of function has been considered the main Experimental Procedures
stream of the pathophysiology in polyQ diseases, but a
loss of function of mutant proteins may also play a role Transgene Construction
Chicken -actin promoter-driven AR-24Q and AR-97Q constructs(Zoghbi and Orr, 2000; Rubinsztein, 2002). Although the
were prepared by digestion of pCAGGS vector (Niwa et al., 1991)expansion of polyQ tract in AR deteriorates the tran-
by HindIII and ligation after filling in, which generated the new NheIscriptional activities of AR, and affects its interaction
site (pCAGGS-NheI). The full-length human AR fragment harboring
with other transcriptional factors and activators (Mhatre 24 or 97 CAGs (Kobayashi et al., 1998) was subcloned into pCAGGS-
et al., 1993; Kazemi-Esfarjani et al., 1995; Chamberlain NheI. By direct DNA sequencing, the presence of 24 and 97 CAG
et al., 1994; Nakajima et al., 1996), the neurologic impair- repeat sequences was confirmed in the 5.3 and 5.5 kb inserts, re-
spectively.ment in SBMA cannot be attributed to the loss of AR
function (Maclean et al., 1995; McPhaul et al., 1993), a
Generation and Maintenance of Tg Mice and Genotypingreason why testosterone shows insufficient and tran-
The final plasmids with SalI-NheI were digested to remove the ARsient effects when used as a therapeutic agent for SBMA
fragments. We generated Tg mice by microinjection into BDF1 fertilized(Danek et al., 1994; Goldenberg and Bradley, 1996;
eggs, and obtained three founders with AR-24Q and five founders with
Neuschmid-Kaspar et al., 1996). The present study fur- AR-97Q. These mice were backcrossed to C57BL/6J. We screened
ther suggests that the major pathogenic mechanism of mouse tail DNA by PCR for the presence of the transgene using the
SBMA is a toxic gain of function of mutant AR with primers 5
-CTTCTGGCGTGTGACCGGCG -3
 and 5
-TGAGCTTGG
expanded polyQ, particularly when located in the nuclei. CTGAATCTTCC-3
 and the confirmation of the CAG repeat size
using the primers 5
-CCAGAGCGTGCGCGAAGTG-3
 and 5
-TGTGAAlthough molecular mechanisms still remain to be eluci-
AGGTTGCTGTTCCTC-3
. The transgene copy number in each linedated, several studies have revealed that nuclear accu-
was determined by densitometric comparison of Southern blot hy-mulation of the mutant protein resulted in sequestration
bridization intensity of the AR DNA with known standards cutting
of transcriptional regulatory proteins in SBMA and other only one site in the transgene using SacII. For determining CAG
polyQ diseases (McCampbell et al., 2000; Steffan et al., repeat size, we electrophoresed the PCR products amplified with
2000; Nucifora et al., 2001). a Texas Red-labeled primer on 6% denaturing polyacrylamide gel
for 12 hr using a 5500 DNA sequencer (Hitachi, Tokyo, Japan).There have been no substantially effective therapeutic
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Neurological and Behavioral Testing area of the anterior horn cells, 20 serial 5 m thick sections from
the fifth lumbar spinal cords of three mice of each group (#7–8, 13-We analyzed rotarod task of mice by an Economex Rotarod (Co-
lombus Instruments, Colombus, Ohio) weekly during the light phase week-old) were prepared. Every other section was stained by the
Nissl technique and all neurons with an obvious nucleolus, presentof the 12 hr light/12 hr dark cycle as described previously (Adachi
et al., 2001). We performed three trials, and recorded the longest in the anterior horn, were assessed using a Luzex FS image analyzer
(Nireco, Tokyo, Japan) as described before (Terao et al., 1996).duration on the rod for every mouse. We stopped the timer when
the mouse fell from the rod or after an arbitrary limit of 180 s. The diameter of myelinated fibers in the ventral spinal roots was
measured on the transverse sections stained with toluidine blue asWe measured cage activity while each mouse was in a transparent
acrylic cage (16  30  14 cm, width  depth  height) housed in described before (Terao et al., 1996).
a soundproofed box. We used an AB system (Neuroscience, Tokyo,
Japan) with an infrared ray sensor monitor to measure spontaneous Statistical Analysis
motor activity. We automatically totaled and recorded all measure- We analyzed data using the unpaired t test and denoted p values
ments for 24 hr per week at 10 min intervals. of 0.05 or less as statistical significance.
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